Blood Res.  2019 Sep;54(3):159-161. 10.5045/br.2019.54.3.159.

Optimizing carfilzomib use in multiple myeloma treatment

• Yoon SS

• KMID: 2459377
• DOI: http://doi.org/10.5045/br.2019.54.3.159

Abstract

No abstract available.

MeSH Terms

Multiple Myeloma*

Figure

• 

  Fig. 1 Overview of carfilzomib use at Seoul National University Hospital since 2016. Abbreviations: KRd, carfilzomib, lenalidomide, dexamethasone; Rd, lenalidomide, dexamethasone; tx, treatment; VMP, bortezomib, melphalan, prednisone; VTD, bortezomib, thalidomide, dexamethasone.

• 

  Fig. 2 PFS following KRd between bortezomib-responsive patients versus bortezomib-refractory patients. Abbreviations: KRd, carfilzomib, lenalidomide, dexamethasone; PFS, progression-free survival.

Reference

1. Mateos MV, Goldschmidt H, San-Miguel J, et al. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018; 36:463–470.

2. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372:142–152.

3. Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017; 177:404–413.

4. Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017; 7:e554.

5. Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019; 9:44.

6. Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014; 99:408–416.

7. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017; 376:1311–1320.

8. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007; 13:183–196.

9. Hagen PA, Stiff P. The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma. Biol Blood Marrow Transplant. 2019; 25:e98–e107.